Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

ECRI Institute and the FDA are co-sponsoring a free public conference on the evidence, programs, and implications of patient-centeredness in healthcare on November 29-30, 2011.

ECRI Institute, an independent nonprofit that researches the best approaches to improving patient care, and the U.S. Food and Drug Administration (FDA) are co-sponsoring a free public conference on the evidence, programs, and implications of patient-centeredness in healthcare on November 29-30, 2011, at the FDA’s White Oak Campus in Silver Spring, MD. 

Patient-Centeredness in Policy and Practice: A Conference on Evidence, Programs, and Implications, ECRI Institute’s 18th annual conference, features more than 40 distinguished speakers, including Margaret Hamburg, MD, Commissioner, FDA; Carolyn Clancy, MD, Director, Agency for Healthcare Research and Quality; Karen Ignagni, President and CEO, America’s Health Insurance Plans; Jeffrey Shuren, MD, JD, Director, Center for Devices and Radiological Health, FDA; Janet Woodcock, MD, Director, Center for Drug Evaluation and Research, FDA; and Joe V. Selby, MD, MPH, Executive Director, Patient-Centered Outcomes Research Institute. 

“This conference comes at a critical moment because the elements of patient-centeredness are in play in significant ways,” says Jeffrey C. Lerner, PhD, President and CEO, ECRI Institute. “FDA regulates 25 cents of every dollar consumers spend, so it makes sense to co-sponsor this wide-ranging conference with them,” adds Lerner. 

The term “patient-centeredness” is now enshrined in law by the Affordable Care Act, which created the new Patient-Centered Outcomes Research Institute. Patient-centeredness is increasingly embedded in program developments at the federal and state level, and in the private sector, too. But what does patient-centeredness actually mean? What programs are working and how do we know? Will patient-centeredness have staying power? Is there a business case for patient-centeredness?

“The patient is the ultimate beneficiary of innovative medical technology,” said Jeffrey Shuren, MD, director of the FDA’s Center for Devices and Radiological Health. “Patient experience can help FDA make better informed benefit-risk determinations.”

The two-day program features eleven sessions that move progressively from theme to theme so that attendees who participate from the first through the last session will gain a coherent understanding of many of the most crucial elements in the movement towards patient centeredness. Day 1 sessions cover researching and regulating for patient-centeredness; health law; patient-centeredness as a core medical skill; the use of evidence in patient-centered informed consent; quality measurement in building accountability; and  communicating evidence-based information as well as influencing consumer perception and behavior through social media and behavioral economics. 

Day 2 sessions examine the use of technology in patient reporting; FDA’s perspective on the role that patients play in the life cycle of medical products; patient centeredness in health systems; federal and state models; and an important closing session on the business case for patient centeredness. 

NOTE: Press are encouraged to attend this live event. Requests to interview any of the speakers should be sent in advance to Laurie Menyo, Director of Public Relations, ECRI Institute, at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or (610) 825-6000, ext. 5310

Source: ECRI Institute